Skip to content
2000
Volume 22, Issue 16
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The emergence of the pathogen Candida auris is a real concern worldwide, especially due to its multidrug resistance profile, besides the difficulties in establishing the correct identification by conventional laboratory methods and its capacity of causing outbreaks in healthcare settings. The limited arsenal of available antifungal drugs, coupled with the lack of momentum for the development of new reagents, represent a challenge in the management of such a pathogen. In this perspective, we have focused on discussing new, promising treatment options for C. auris infections. These novel drugs include an antifungal agent already approved for medical use in the United States of America, compounds that are already in clinical trials and those with potential for repurposing use against this important fungal pathogen.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026622666220520153748
2022-06-01
2025-09-03
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026622666220520153748
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test